DRMA
Dermata Therapeutics, Inc. [DRMA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DRMA Stock Summary
In the News
DRMA Financial details
Company Rating
-
Market Cap
2.74M
Income
-7.76M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
16 May 2024
P/E
-0.26
Forward P/E
-
PEG
0.04
P/S
-
P/B
0.29
P/C
-
P/FCF
-0.3
Quick Ratio
7.23
Current Ratio
7.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.94
EPS next Y
-
EPS next Q
-
EPS this Y
-80.82%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-98%
ROE
-101%
ROC
-1.18%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.37-3.93
52W High
-
52W Low
-
RSI
56
Rel Volume
0.54
Avg Volume
139.38K
Volume
75.34K
Perf Week
7.55%
Perf Month
14.28%
Perf Quarter
-21.96%
Perf Half Y
-28.1%
-
-
-
-
Beta
0.872
-
-
Volatility
0.04%, 0.05%
Prev Close
3.22%
Price
1.2799
Change
10.34%
Company Profile
- Volume Average 139.38K
- Market Capitalization 2.74M
- Employee 8
- CEO Mr. Gerald T. Proehl
- Headquarters San Diego,CA,US
- IPO Date 2021-08-13
-
Website
https://www.dermatarx.com 
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
